Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban micronized - film coated tablets - rivaroxaban micronized 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.